Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 68083-650

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 68083-650). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bortezomib-spl-1mg-carton (Bortezomib Spl 1mg Carton)

This text provides important information about a medication called Bortezomib, available in single-dose vials for intravenous or subcutaneous use. It includes instructions for reconstitution, recommended dosage, storage conditions, and details on the hazardous nature of the agent. The content also specifies the manufacturer as Gland Pharma Limited in India. It is crucial to follow the prescribing information and reconstitution guidelines mentioned on both sides of the carton for safe and effective use.*

FDA Label Image

Bortezomib-spl-1mg-container (Bortezomib Spl 1mg Container)

This is a prescription medication with the NDC code 68083-650-01 for Bortezomib for Injection. It is manufactured by Sammc Gland Pharma Limited in India. The medication is available in single-dose vials for intravenous or subcutaneous use. It is important to discard any unused portion of the medication properly. The label warns that the medication is a hazardous agent.*

FDA Label Image

Bortezomib-spl-2-5mg-carton (Bortezomib Spl 2 5mg Carton)

This text provides detailed instructions and information about a medication called Bortezomib for injection. It includes reconstitution information, recommended dosage, storage instructions, and cautions. The medication is manufactured by Gland Pharma Limited in India and contains bortezomib and mannitol. It is intended for subcutaneous or intravenous use and must be discarded if unused. The text also mentions specific concentrations and additives required for reconstitution.*

FDA Label Image

Bortezomib-spl-2-5mg-container (Bortezomib Spl 2 5mg Container)

This text contains information about Bortezomib for Injection, a medication used for intravenous or subcutaneous use. Each single-dose vial contains 2.5 mg of Bortezomib and 25 mg of Mannitol. It is a hazardous agent and caution should be taken. The recommended dosage can be found in the prescribing information. Storage instructions include keeping it at 20°C to 25°C (68° to 77°F) and protecting it from light. The medication is manufactured by Gland Pharma Limited in India.*

FDA Label Image

Bortezomib-spl-figure-1.jpg (Bortezomib Spl Figure 1)

FDA Label Image

Bortezomib-spl-figure-2.jpg (Bortezomib Spl Figure 2)

FDA Label Image

Bortezomib-spl-figure-3.jpg (Bortezomib Spl Figure 3)

FDA Label Image

Bortezomib-spl-figure-4.jpg (Bortezomib Spl Figure 4)

FDA Label Image

Bortezomib-spl-figure-5.jpg (Bortezomib Spl Figure 5)

FDA Label Image

Bortezomib-spl-figure-6.jpg (Bortezomib Spl Figure 6)

FDA Label Image

Bortezomib-spl-structure.jpg (Bortezomib Spl Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.